Anti‐PD‐L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma

Immunotherapy based on blockade of the programmed death‐1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) axis has shown promising clinical activity for renal cell carcinoma (RCC) patients; however, the most effective use of these agents in combination with conventional targeted therapy remains to be resol...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirayama, Yukiyoshi, Gi, Min, Yamano, Shotaro, Tachibana, Hirokazu, Okuno, Takahiro, Tamada, Satoshi, Nakatani, Tatsuya, Wanibuchi, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198964/
https://www.ncbi.nlm.nih.gov/pubmed/27712020
http://dx.doi.org/10.1111/cas.13099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198964/
https://www.ncbi.nlm.nih.gov/pubmed/27712020
http://dx.doi.org/10.1111/cas.13099

Ejemplares similares